candesartan has been researched along with Stroke in 68 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 9.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 9.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "SCAST was an international multicentre, randomized and placebo-controlled trial of candesartan in 2029 patients recruited within 30 h of acute ischaemic or haemorrhagic stroke." | 9.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
| "SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 9.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 9.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 9.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke." | 9.14 | Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010) |
| "In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihypertensive treatment, despite little difference in blood pressure reduction." | 9.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia." | 7.81 | Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015) |
| "Stroke is a leading cause of death and disability." | 7.81 | Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. ( Doggrell, SA, 2004) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 7.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| "Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats." | 7.76 | Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 7.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 7.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 7.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| " This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins." | 7.74 | Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008) |
| "We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome." | 7.74 | Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008) |
| "Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt." | 7.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| "Stroke is a major cause of mortality and disability worldwide." | 6.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "Ischemic stroke is a leading cause of disability." | 5.34 | Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 5.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 5.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke." | 5.20 | Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC; Sandset, PM, 2015) |
| "The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 5.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "SCAST was an international multicentre, randomized and placebo-controlled trial of candesartan in 2029 patients recruited within 30 h of acute ischaemic or haemorrhagic stroke." | 5.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke." | 5.20 | Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. ( Bath, PM; Berge, E; Jusufovic, M; Karlson, BW; Sandset, EC, 2015) |
| "SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 5.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 5.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke." | 5.16 | Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 5.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| "The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke." | 5.14 | Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihypertensive treatment, despite little difference in blood pressure reduction." | 5.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "The Study on COgnition and Prognosis in the Elderly (SCOPE) assessed the effect of candesartan on cardiovascular outcomes in elderly patients with mild to moderate hypertension." | 5.11 | The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. ( Elmfeldt, D; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2005) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia." | 3.81 | Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015) |
| "Stroke is a leading cause of death and disability." | 3.81 | Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. ( Doggrell, SA, 2004) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| " Candesartan suppressed the development of lipoatrophy and reduced the incidence of stroke at 20 weeks of age." | 3.79 | Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats. ( Inoue, T; Ito, H; Takemori, K, 2013) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 3.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 3.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats." | 3.76 | Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 3.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 3.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| "We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome." | 3.74 | Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| " This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins." | 3.74 | Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008) |
| "Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt." | 3.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| " Perindopril, candesartan cilexetil, or amlodipine alone or the combination of low doses of each agent was administered orally to stroke-prone spontaneously hypertensive rats (SHRSP) for 4 weeks to compare the hypotensive or cardiovascular effects." | 3.70 | Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. ( Iwao, H; Izumi, Y; Kim, S; Zhan, Y, 2000) |
| "Candesartan was associated with improved whole brain CVR compared to placebo in the CEDAR study (adjusted within-group mean difference for candesartan = 0." | 3.01 | Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. ( Hajjar, I; Henley, B; Kulshreshtha, A; Okafor, M; Trammell, A, 2023) |
| "Stroke is a major cause of mortality and disability worldwide." | 2.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "The development of new treatments for acute stroke has been fraught with costly and spectacularly disappointing failures." | 2.46 | Drug repurposing for drug development in stroke. ( Fagan, SC, 2010) |
| "As stroke is characterised by vascular remodelling and dysfunction and by effects on the cerebral circulation, selecting an agent that has a direct vascular protective effect beyond blood pressure control may be desirable." | 2.42 | Stroke prevention: is it possible? If so, which antihypertensive agent should be used? ( Kim, S, 2003) |
| "Arterial hypertension is closely correlated with the occurrence of stroke and also with the loss of cognitive function and dementia." | 2.42 | Neurological protection provided by candesartan: reviewing the latest study results. ( Leys, D, 2003) |
| "Stroke is a leading cause of adult disability worldwide." | 1.46 | Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension. ( Ahmed, H; Alhusban, A; Ergul, A; Fagan, SC; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Sayed, MA, 2017) |
| "However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke." | 1.35 | Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009) |
| "Ischemic stroke is a leading cause of disability." | 1.34 | Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 1.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (52.94) | 29.6817 |
| 2010's | 31 (45.59) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Henley, B | 1 |
| Okafor, M | 1 |
| Kulshreshtha, A | 1 |
| Trammell, A | 1 |
| Hajjar, I | 1 |
| Alhusban, A | 2 |
| Kozak, A | 5 |
| Pillai, B | 4 |
| Ahmed, H | 1 |
| Sayed, MA | 1 |
| Johnson, MH | 4 |
| Ishrat, T | 5 |
| Ergul, A | 6 |
| Fagan, SC | 9 |
| Culman, J | 3 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 3 |
| Gohlke, P | 2 |
| Hornslien, AG | 3 |
| Sandset, EC | 10 |
| Bath, PM | 8 |
| Wyller, TB | 2 |
| Berge, E | 10 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Takemori, K | 1 |
| Inoue, T | 1 |
| Ito, H | 1 |
| Kikuchi, K | 1 |
| Tancharoen, S | 1 |
| Ito, T | 1 |
| Morimoto-Yamashita, Y | 1 |
| Miura, N | 1 |
| Kawahara, K | 1 |
| Maruyama, I | 1 |
| Murai, Y | 1 |
| Tanaka, E | 1 |
| Hafez, S | 1 |
| Soliman, S | 2 |
| Pillai, A | 1 |
| Somanath, PR | 1 |
| El-Remessy, AB | 2 |
| Fouda, AY | 2 |
| Jusufovic, M | 4 |
| Karlson, BW | 1 |
| Sandset, PM | 1 |
| Igland, J | 1 |
| Terént, A | 3 |
| Boysen, G | 3 |
| Murray, GD | 3 |
| Abdul-Rahim, AH | 1 |
| Perez, AC | 1 |
| Fulton, RL | 1 |
| Jhund, PS | 1 |
| Latini, R | 1 |
| Tognoni, G | 1 |
| Wikstrand, J | 1 |
| Kjekshus, J | 1 |
| Lip, GY | 1 |
| Maggioni, AP | 1 |
| Tavazzi, L | 1 |
| Lees, KR | 1 |
| McMurray, JJ | 1 |
| Eldahshan, W | 1 |
| Waller, JL | 1 |
| Kozak, W | 1 |
| Elewa, HF | 2 |
| Kato, N | 1 |
| Liang, YQ | 1 |
| Ochiai, Y | 1 |
| Birukawa, N | 1 |
| Serizawa, M | 1 |
| Jesmin, S | 1 |
| Machado, LS | 1 |
| Abdelsaid, M | 1 |
| Wiley, DC | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 1 |
| Honda, T | 1 |
| Haze, K | 1 |
| Nagashima, M | 1 |
| Yamaguchi, J | 1 |
| Origasa, H | 1 |
| Urashima, M | 1 |
| Ogawa, H | 2 |
| Mecca, AP | 1 |
| O'Connor, TE | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Kjeldsen, SE | 3 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Saad, MA | 1 |
| Abbas, AM | 1 |
| Boshra, V | 1 |
| Elkhateeb, M | 1 |
| El Aal, IA | 1 |
| Murray, G | 1 |
| Jatuzis, D | 2 |
| Kõrv, J | 2 |
| Lüders, S | 3 |
| Richter, PS | 2 |
| Roine, RO | 2 |
| Thijs, V | 2 |
| Gaur, V | 1 |
| Kumar, A | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Shimosato, T | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Schmerbach, K | 1 |
| Pfab, T | 1 |
| Mueller, S | 1 |
| Villringer, A | 2 |
| Muller, DN | 1 |
| Hocher, B | 1 |
| Unger, T | 2 |
| Thoene-Reineke, C | 1 |
| Hankey, GJ | 1 |
| Hedner, T | 1 |
| Narkiewicz, K | 1 |
| Oparil, S | 1 |
| Arima, H | 1 |
| Chalmers, J | 1 |
| Guan, W | 1 |
| Castilla-Guerra, L | 1 |
| Fernández-Moreno, MC | 1 |
| Álvarez-Suero, J | 1 |
| Jiménez Hernández, MD | 1 |
| Kim, S | 3 |
| Leys, D | 1 |
| Mansour, J | 1 |
| Peltier, M | 1 |
| Oprisiu, R | 2 |
| Achard, JM | 3 |
| Fournier, A | 3 |
| Christensen, H | 1 |
| Doggrell, SA | 1 |
| Schrader, J | 1 |
| Diener, HC | 1 |
| Kumagai, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Saruta, T | 1 |
| Williams, B | 1 |
| Papademetriou, V | 2 |
| Farsang, C | 1 |
| Elmfeldt, D | 2 |
| Hofman, A | 2 |
| Lithell, H | 3 |
| Olofsson, B | 2 |
| Skoog, I | 2 |
| Trenkwalder, P | 2 |
| Zanchetti, A | 2 |
| Lundkvist, J | 1 |
| Ekman, M | 1 |
| Kartman, B | 1 |
| Carlsson, J | 1 |
| Jönsson, L | 1 |
| Kim-Mitsuyama, S | 2 |
| Yamamoto, E | 2 |
| Tanaka, T | 1 |
| Zhan, Y | 2 |
| Izumi, Y | 2 |
| Izumiya, Y | 1 |
| Ioroi, T | 1 |
| Wanibuchi, H | 1 |
| Iwao, H | 2 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Suzuki, H | 3 |
| Kanno, Y | 3 |
| Nakamura, T | 3 |
| Takenaka, T | 1 |
| Kohara, K | 1 |
| Brdon, J | 1 |
| Kaiser, S | 1 |
| Hagemann, F | 1 |
| Serot, JM | 1 |
| Black, SE | 1 |
| Hallevi, H | 2 |
| Hazan-Halevy, I | 1 |
| Paran, E | 2 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Rojas, A | 1 |
| González, I | 1 |
| Figueroa, H | 1 |
| Hazan-Hallevi, I | 1 |
| Krikov, M | 1 |
| Thone-Reineke, C | 1 |
| Müller, S | 1 |
| Ikeda, Y | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Mochizuki, S | 1 |
| Yoshida, Y | 1 |
| Jiménez, AM | 1 |
| Montón, M | 1 |
| García, R | 1 |
| Núñez, A | 1 |
| Gómez, J | 1 |
| Rico, L | 1 |
| García-Colis, E | 1 |
| de Miguel, LS | 1 |
| Arriero, MM | 1 |
| Cabestrero, F | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Dalmay, F | 1 |
| Mazouz, H | 1 |
| Allard, J | 1 |
| Pesteil, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for candesartan and Stroke
| Article | Year |
|---|---|
Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials.
Topics: Aged; Alzheimer Disease; Carbon Dioxide; Cognitive Dysfunction; Female; Humans; Lisinopril; Male; Ra | 2023 |
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou | 2013 |
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; | 2015 |
Drug repurposing for drug development in stroke.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Discovery; Humans; Stroke | 2010 |
Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Neurological protection provided by candesartan: reviewing the latest study results.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2003 |
Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Scope].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
Protection against stroke and dementia: an update on the latest clinical trial evidence.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2004 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
[Study on cognition and prognosis in the elderly].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2006 |
[E-COST].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2006 |
17 trials available for candesartan and Stroke
| Article | Year |
|---|---|
Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Diso | 2013 |
Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Female; Huma | 2014 |
Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2015 |
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; D | 2015 |
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; F | 2015 |
Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphen | 2015 |
Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2009 |
Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003).
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Hu | 2010 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2012 |
Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2005 |
The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2005 |
Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2005 |
39 other studies available for candesartan and Stroke
| Article | Year |
|---|---|
Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; | 2017 |
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl | 2013 |
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2013 |
Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B.
Topics: Angiopoietin-1; Animals; Benzimidazoles; Biphenyl Compounds; Cell Culture Techniques; Cell Line; Cel | 2014 |
Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Disease Models, Animal; Male; Neuronal | 2015 |
Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.
Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Benzim | 2017 |
Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hyper | 2008 |
Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2008 |
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compoun | 2009 |
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor | 2010 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Bi | 2011 |
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blo | 2011 |
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
Topics: Amides; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzimidaz | 2010 |
Lowering blood pressure in acute stroke: the SCAST trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2011 |
Treatment of high blood pressure in acute stroke--the SCAST study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; M | 2011 |
Stroke: blood pressure lowering in acute stroke--scant joy from SCAST.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bip | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl C | 2011 |
[In view of the findings of the SCAST study, must the treatment of arterial pressure in the acute phase of stroke be changed?].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topi | 2011 |
[AT1 blocker therapy of hypertension in seniors. Added protection for cerebral blood vessels?].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2003 |
The CHARM programme.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2003 |
Hypertension in acute stroke.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Humans; | 2003 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
[Treating high blood pressure in acute stroke].
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2004 |
Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2005 |
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Treating stroke in the 21st century.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Erythropoietin; Humans; | 2007 |
Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cell Adhes | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam | 2008 |
The ECV-304 cell-line: should it be used?
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel | 2008 |
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Brain-Derived | 2008 |
Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2000 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2001 |
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; B | 2001 |